Evaluation of the Eyelash Care Effects of Premium Rejuvenation Eyelash Serum
| Registry | NCT07271199 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: triple, other |
| Enrollment | 30 (Actual) |
| Sponsor | Hungkuang University (Other); collaborators: Schweitzer Biotech Company |
| Conditions | Skin Condition, Eyelash Growth, Eyelashes, Skin Health, Hair Health |
| Interventions | Placebo control, Experimental formula (Other) |
| Dates | start 2025-11-01, primary completion 2026-05-26, completion 2026-05-26, first posted 2025-12-09, last updated 2026-06-12 |
| Locations | 1 site in Taiwan |
Related Papers Related Patents Related Grants Related Experts
All trials for Skin Condition All trials for Eyelash Growth All trials of Placebo control All trials of Experimental formula
This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups to receive either test product or placebo at 1:1 ratio. Participants will apply the product twice daily for 56 days (8 weeks), with eyelash and periorbital skin conditions assessed at multiple time points using non-invasive measurements. Key parameters include eyelash density, eyelash length, and overall periorbital skin condition. At the end of the study (Day 56), participant will be asked to fill out a questionnaire on the usage of the intervention and self evaluation of eyelash condition.
This prospective, randomized, double-blinded, placebo-controlled study aims to investigate the effects of Premium Rejuvenation Eyelash Serum on eyelashes and surrounding periorbital skin. A total of 30 healthy female adults aged 18 to 60 will be enrolled. Inclusion criteria require participants to be free from chronic diseases, major illnesses (including cancer, stroke-related disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, or major organ/hematopoietic stem cell transplants), and allergic constitutions. Exclusion criteria include current use of medications or eyelash care products.
Participants will be randomly assigned into two groups of 15 each: Group 1 uses placebo (Base formula without active ingredient); Group 2 uses the experimental formula with ginger (Zingiber officinale)-derived extracellular vesicle + turmeric (Curcuma longa)-derived extracellular vesicles + IGF-1 + FGF-7. Baseline assessments will be conducted prior to product use. Follow-up assessments will occur at Days 28 (4 weeks) and 56 (8 weeks). Evaluations will include eyelash density, change in eyelash length, self-reported periorbital skin condition (e.g., swelling, irritation, pigmentation, redness, and allergic reactions), and a questionnaire. Eyelash parameters will be objectively measured using the Canfield Scientific VISIA® Skin Analysis System. At the conclusion of the study (Day 56), participant self-assessments on the intervention and eyelash condition will be evaluated through a questionnaire.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Group 1: Placebo control | Placebo comparator | Other: Placebo control | Base formula without active ingredient |
| Group 2: Experimental formula | Experimental | Other: Experimental formula | Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7). |
Sex: Female, ages: 18 Years to 60 Years, accepts healthy volunteers
Inclusion Criteria: * Healthy female adults from the age of 18 to 60 years (inclusive). * Having symptoms of alopecia, baldness, or self-identified with hair thinning. * Absence of chronic diseases, major illnesses, or allergies. * Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant Exclusion Criteria: * Currently taking any medication or using any eyelash care products.
| Facility | City | Country | Status |
|---|---|---|---|
| Hungkuang University | Taichung | Taiwan |